Drugs / TIMAPIPRANT
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03942666 | May → Nov 2019 | asthma | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 1 | NCT02341521 | Mar → May 2015 | asthma | Atopix Therapeutics, Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01056575 | Feb → Apr 2010 | — | Oxagen Ltd | Completed | No outcome recorded |
| Phase 27 trials · 2 missed | ||||||
| Phase 2 | NCT02660489 | Jan 2015 → Feb 2018 | Picornaviridae infectious disease, asthma, common cold | Imperial College London | Completed | Missed primary |
| Phase 2 | NCT02002208 | Oct 2013 → Sep 2015 | atopic eczema | Atopix Therapeutics, Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01056783 | Aug 2010 → Jun 2011 | eosinophilic esophagitis | Oxagen Ltd | Completed | No outcome recorded |
| Phase 2 | NCT00890877 | Apr 2009 → May 2010 | chronic asthma | Oxagen Ltd | Completed | No outcome recorded |
| Phase 2 | NCT00697281 | May → Jul 2008 | allergic rhinitis | Oxagen Ltd | Completed | No outcome recorded |
| Phase 2 | NCT01448902 | Mar → May 2007 | allergic rhinitis | Oxagen Ltd | Completed | No outcome recorded |
| Phase 2 | NCT01057927 | Jan → Nov 2007 | asthma | Oxagen Ltd | Completed | Missed primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT04049175 | Aug 2019 → Oct 2020 | asthma | Chiesi Farmaceutici S.p.A. | Terminated | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT02560610 Comparator | Sep 2016 → Aug 2018 | lower respiratory tract disorder | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT01056692 Comparator | Feb 2006 → ? | asthma | Oxagen Ltd | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TIMAPIPRANT | ChEMBL registry synonym — accepted as the source's own label CHEMBL560993 ↗ |
| Known as | CHF 6532 | “Tablet of CHF 6532” NCT04049175 ↗1“tablet of CHF 6532” NCT03942666 ↗ |
| Known as | OC000459 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00890877 ↗ |
| Known as | OC459 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02660489 ↗ |
| Known as | Odc-9101 | ChEMBL registry synonym — accepted as the source's own label CHEMBL560993 ↗ |
| Action | Activate | “Cytochrome P 450 3A4 Induction by Oral OC000459” NCT01056575 ↗ |
| Action | Inhibit | “G protein-coupled receptor 44 antagonist” CHEMBL560993 ↗ |
| Modality | Small molecule | — CHEMBL560993 ↗ |
| Route | Oral | “OC000459 given orally for eight days” NCT00697281 ↗ |
| Target | CYP3A4 | “Cytochrome P 450 3A4 Induction by Oral OC000459” NCT01056575 ↗ |
| Target | PTGDR2 | “G protein-coupled receptor 44 antagonist” CHEMBL560993 ↗ |